A Non-interventional, Post-authorisation Safety Study of Patients Treated With Efgartigimod Alfa

a study on Myasthenia Gravis

Summary

Eligibility
for people ages 18 years and up (full criteria)
Location
at San Francisco, California and other locations
Dates
study started
study ends around

Description

Summary

This is a non-interventional, prospective, post authorization safety study. Patients with gMG who are expected to start treatment with efgartigimod at enrolment or are within their first cycle of efgartigimod at enrolment will be eligible to enroll into the efgartigimod cohort. Patients with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment will be eligible to enroll into the non-efgartigimod cohort.

Keywords

Myasthenia Gravis, efgartigimod alfa, efgartigimod

Eligibility

You can join if…

Open to people ages 18 years and up

  • Patients diagnosed with gMG who are expected to start commercial efgartigimod at enrolment or who are within their first cycle of efgartigimod at enrolment or Patients diagnosed with gMG who have not been exposed to efgartigimod and for whom it is not planned to start treatment with efgartigimod at enrolment
  • Have provided appropriate written informed consent

You CAN'T join if...

  • None

Locations

  • UCSF Medical Center - Helen Diller Family Comprehensive Cancer Center - Brain Tumor Center, accepting new patients
    San Francisco California 94143 United States
  • Oregon Health and Science University accepting new patients
    Portland Oregon 97239 United States
  • University of Colorado Hospital accepting new patients
    Portland Oregon 97239 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
argenx
ID
NCT06298565
Study Type
Observational
Participants
Expecting 680 study participants
Last Updated
Contact us about this trial